Mitochondria in Extracellular Vesicles and Aging

Mitochondria 2022 speakers-Nicole Noren HootenDr. Nicole Noren Hooten from NIH, USA will join us this year to present her most recent findings on "Mitochondria in Extracellular Vesicles and Aging" in a session entitled "Extracellular Vesicles & Mitochondria: The Target".

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers like Dr. Hooten. Remember that you too can present your most recent findings related to this session by submitting your abstract.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

Targeting Mitochondria 2022 will be held at Steigenberger Am kanzleramt, Berlin

Steigenberger Am kanzleramt Berlin
Congress venue:

Steigenberger Hotel Am Kanzleramt Hotel

Ella-Trebe-Straße 5, 10557 Berlin, Germany


Special Rate for Room Booking at
Steigenberger Hotel Am Kanzleramt

Targeting Mitochondria Committee offers to the congress attendees a special privileged rate for your booking:

Single Superior room: 169€ by night (breakfast, tax included)
Double Superior Room: 189€ by night (breakfast, tax included)
 
Important Information:

This deal is limited in time and in number of rooms: First booked, first served!
When your booking will be done, you will receive an email of confirmation.

Book your Hotel Room here.
Please note that Hotel Booking is available until August 30, 2022, with the link above.


For more information about access and hotel, please visit the hotel website.

Prof. Wallace: Keynote Speaker at WMS 2022

Mitochondria 2022 Mitochondrial Medicine present and future

It is a great pleasure to welcome Prof. Douglas C. Wallace, Children's Hospital of Philadelphia, USA, at Targeting Mitochondria 2022 congress. He will introduce the meeting with a keynote speech on Mitochondrial Medicine : Present and Future.

Read more...

The Impact of Mesenchymal Stromal Cell Extracellular Vesicles on Mitochondrial Dysfunction in Acute Respiratory Distress Syndrome

Mitochondria 2022 Dr. Anna KrasnodembskayaDr. Anna Krasnodembskaya from Queen's University Belfast, The United Kingdom,  will join us this year to present her most recent findings on "The Impact of Mesenchymal Stromal Cell Extracellular Vesicles on Mitochondrial Dysfunction in Acute Respiratory Distress Syndrome" in a session entitled "Extracellular Vesicles & Mitochondria: The Target".

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers like Dr. Krasnodembskaya. Remember that you too can present your most recent findings related to this session by submitting your abstract.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

Autologous Mitochondrial Transplant for Cerebral Ischemia

Mitochondria 2022 Dr. Melanie WalkerDr. Melanie Walker from the University of Washington Medical School, USA,  will join us this year to present her most recent findings on "Autologous Mitochondrial Transplant for Cerebral Ischemia".

Stroke is one of the leading causes of morbidity and mortality worldwide. More than 80% of strokes are the result of ischemia caused by blockage of one or more cerebral arteries. Lack of blood supply starves brain cells of necessary glucose and oxygen, and disturbs cellular homeostasis, eventually resulting in neuronal death. Based on many preclinical studies in animals, damage caused by ischemia can be reversed after infusing healthy mitochondria into injured tissues. An ongoing clinical trial in human hearts at Boston Children's Hospital has also demonstrated that transplanting autologous mitochondria via infusion or direct injection is well-tolerated and safe.

Dr. Walker and her clinical research team are currently recruiting for a first-in-human-brain trial to assess the safety of mitochondrial transplantation for ischemic-reperfusion injury in the brain. She will discuss their preclinical studies and status of their clinical trial.

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers like Dr. Walker. Book your spot.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

Mitochondrial and Photo-Medicine - Recent Clinical Applications

Mitochondria 2022 speaker - Michael WeberDr. med. Michael Weber, President of European Laser Academy, Germany will join us this year to present his most recent findings on "Mitochondrial and Photo-Medicine - Recent Clinical Applications".

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers like Dr. WeberBook your spot.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

Folic Acid Supplementation Improves Drosophila Parkin Loss-of-Function Phenotype and Decreases Mitochondrial Hydrogen Peroxide Levels in Vulnerable Dopaminergic Neurons

Dr Lori BuhlmanDr. Lori Buhlman, from Midwestern University Glendale, USA, will join us this year to present her most recent findings on "Folic Acid Supplementation Improves Drosophila Parkin Loss-of-Function Phenotype and Decreases Mitochondrial Hydrogen Peroxide Levels in Vulnerable Dopaminergic Neurons".

A major hallmark of Parkinson’s disease (PD) is selective degeneration of dopaminergic neurons within the substantia nigra pars compacta. While the vast majority of PD cases are idiopathic, a small percent of patients inherits disease-causing mutations in the PRKN gene, which encodes the parkin protein.

Parkin loss-of-function Drosophila have motor deficits and selective neurodegeneration in the protocerebral posterior later region 1 (PPL1), which is functionally homologous to the human substantia nigra. Dr. Buhlman uses this model to search for unique features that make PPL1 neurons vulnerable.

Mitochondrial dysfunction and oxidative stress are heavily implicated in neurodegeneration; however, how loss of parkin leads to cell death is unclear. Using redox-sensitive cell-specific fluorescent reporters, Dr. Buhlam observed that elevated hydrogen peroxide levels are sustained as the parkin loss-of-function fly ages in PPL1 neurons but not in an unaffected cluster of dopaminergic neurons. Interestingly, demand for glutathione, an important mitochondrial antioxidant, is only elevated in PPL1.

She hypothesized that low levels of glutathione, combined with increases in mitochondrial hydrogen peroxide levels contribute to the dysfunction of mitochondria, oxidative stress and PPL1 neurodegeneration. To address this, she has repeated her study in flies raised on a folic acid-supplemented diet to increase cysteine amino acid synthesis, as cysteine is the rate-limiting component of glutathione synthesis.  Dr. Buhlman has observed increased lifespan, improved motor behavior, and decreased hydrogen peroxide levels in treated flies.

Her results could provide new information regarding the role of parkin in mitochondrial function and disease and indicate candidate therapeutic targets.

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers like Dr. Buhlman. Book your spot.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

 

Noninvasive Treatment of Brain Ischemia-Reperfusion Injury With Near Infrared Light: Working Toward Clinical Implementation

Dr Maik HüttemannDr. Maik Hüttemann, from Wayne State University, USA, will join us this year to present his most recent findings on "Noninvasive Treatment of Brain Ischemia-Reperfusion Injury With Near Infrared Light: Working Toward Clinical Implementation" within a session, chaired by him, entitled "Translational Therapies - Focus on Infrared Therapies".

Dr. Hüttemann has  discovered specific wavelengths of near infrared light (IRL) that target and partially inhibit the mitochondrial enzyme cytochrome c oxidase (COX). Modulation of COX activity via IRL allows him to control the electron transport chain (ETC) and would be therapeutically beneficial in conditions where mitochondria are hyperactive, such as during reperfusion following an ischemic event. ETC hyperactivity is detrimental to neurons because it causes hyperpolarization of the mitochondrial membrane potential during reperfusion, leading to the generation of excessive amounts of reactive oxygen species (ROS).

Dr. Hüttemann shows that noninvasive application of COX-inhibitory IRL in small and large animal models of brain ischemia/reperfusion injury limits ROS production and is highly neuroprotective. To translate these findings into the clinic, efficient and safe IRL delivery to the human head is essential, which is achieved through novel silicone based IRL delivery patches.

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers in this field. Book your spot.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

A Non-canonical Tricarboxylic Acid Cycle Underlies Cellular Identity

Dr Paige ArnoldDr. Paige Arnold, from the Memorial Sloan Kettering Cancer Center, USA, will join us this year to present her most recent findings on Tricarboxylic acid cycle, through a presentation entitled "A Non-canonical Tricarboxylic Acid Cycle Underlies Cellular Identity".

Dr. Arnold states that the tricarboxylic acid (TCA) cycle is a core metabolic pathway that produces reducing equivalents for energy production and critical biosynthetic intermediates. Despite the ubiquitous importance of TCA cycle-derived products for cell viability and proliferation, mammalian cells display significant heterogeneity in TCA cycle activity. The existence of diverse TCA cycle wiring across different cell types led her and her team to hypothesize that TCA cycle enzymes might assemble into multiple pathway configurations. By combining genetic co-essentiality mapping with isotope tracing studies in cancer cells and stem cells, they describe a biochemical alternative to the traditional TCA cycle that is cell-state dependent and required for cell fate transitions.

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers in this field.Book your spot.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

Mitochondria Transplantation Between Living Cells

Dr Julia A. VorholDr. Julia A. Vorholt, from ETH Zurich, Switzerland, will join us this year to present her most recent findings on "Mitochondrial Transplantation Between Living Cells" in a session entitled "Mitochondria Transplantation and Transfer

Mitochondria and the complex endomembrane system are hallmarks of eukaryotic cells. To date, it has been difficult to manipulate organelle structures within single live cells.

Dr. Vorholt developed a FluidFM-based approach to extract, inject and transplant organelles directly from and into living cells with subcellular spatial resolution. The technology combines atomic force microscopy, optical microscopy and nanofluidics to achieve force and volume control with real-time inspection.

The approach enables the transfer of controlled quantities of mitochondria into cells while maintaining their viability and monitoring their fate in new host cells. Transplantation of healthy and drug-impaired mitochondria into primary keratinocytes allows real-time tracking of mitochondrial subpopulation rescue. After transfer of mitochondria into somatic cells and cell propagation over generations, she shows that donor mtDNA was replicated in recipient cells without the need for selection pressure.

The approach opens new prospects for the study of organelle physiology and homeostasis, but also for mechanobiology, synthetic biology, and therapy.

Remember that Targeting Mitochondria 2022 also gives you the chance to present your new research related to this session by submitting your abstract.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

Recent Advances in Mitochondrial Transplantation Therapy

Dr James McCullyDr. James D. McCully, from The Harvard Medical School Department of Cardiac Surgery Boston Children’s Hospital, USA, will join us this year to present his most recent findings on "Recent Advances in Mitochondrial Transplantation Therapy".

Join us in Targeting Mitochondria 2022 and benefit from the experience of professional researchers in this field. Book your spot.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

 

 

 

Regulation of Mitochondrial Signaling in Cardiomyopathy During Sepsis

Dr Qun Sophia ZangDr. Qun Sophia Zang, from Loyola University Chicago Health Science Campus, USA, will join us this year to present her most recent findings on "Regulation of Mitochondrial Signaling in Cardiomyopathy During Sepsis".

The research objective in Dr. Zang’s laboratory is to understand the mechanisms underlying sepsis-induced cardiomyopathy and to identify potential new drug targets for this devastating critical care condition.

In particular, Dr. Zang is interested in how injured mitochondria and related production of mitochondria-derived danger-associated molecular patterns (DAMPs) incite myocardial inflammation, elevate oxidative stress, and cause cardiac dysfunction in sepsis.

She recently discovered the importance of a previously unidentified function of autophagyfactor Beclin-1 in the regulation of mitochondrial quality control in the heart during sepsis.

Her current investigations are designed to decipher the signal transduction of Beclin-1 in the control of cardiacmitochondrial homeostasis via mitophagy and mitochondria-associated membranes in septicsubjects using both genetic and pharmacological approaches.

Remember that you too can join us and present your latest research on the mitochondria by submitting your abstract.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

 

The Randomized Controlled Phase 2b KHENERGYZE Trial of Sonlicromanol in Primary Mitochondrial Disease MELAS Spectrum Disorders: Topline Results

 

Dr Jan SmeitinkDr. Jan Smeitink, from Khondrion B.V., Netherlands, will join us this year to present his most recent findings on "The randomized controlled phase 2b KHENERGYZE trial of sonlicromanol in primary mitochondrial disease MELAS spectrum disorders: topline results" 

MELAS spectrum disorders caused by the 3243A>G mutation in the MT-TL1 gene lead to hampered oxidative phosphorylation with, as immediate cellular consequences, both reductive and oxidative stress.The clinical spectrum is heterogeneous with classical mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) and maternally inherited diabetes mellitus and deafness (MIDD) as most frequently encountered phenotypes. Sonlicromanol modulates key metabolic and inflammatory pathways in the pathogenesis of MELAS-SD models.

Here, Dr. Smeitnik reports the results of a 3-way cross over RCT which, together with the already completed phase 1 and phase 2a trials and the ongoing phase 2b open label extension study, will guide the design of the pivotal KHENERFIN trial. 

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com 

The Role of Extracellular Vesicles in Mitochondrial Quality Control Mechanisms

Dr Marc GermainDr. Marc Germain, from Université du Québec à Trois-Rivières, Canada, will join us this year to present his most recent findings on "The Role of Extracellular Vesicles in Mitochondrial Quality Control Mechanisms" in a session dedicated to "Extracellular Vesicles & Mitochondria: The Target".

Most cells constitutively secrete mitochondrial DNA and proteins in extracellular vesicles (EVs). Dr. Germain, will explain how cells actively prevent the packaging of pro-inflammatory, oxidized mitochondrial proteins that would act as damage-associated molecular patterns (DAMPs) into EVs.  He will describe the selectively targeted pathways responsible for distinction between material to be included into EVs and damaged mitochondrial content to be excluded.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com

Mitochondrial, exosomal miR137-COX6A2 in schizophrenia

Dr Ines KhadimallahDr. Ines Khadimallah, from Lausanne University Hospital, Switzerland, will join us this year to present her most recent findings on "Mitochondrial, exosomal miR137-COX6A2 in schizophrenia".

Dr. Khadimallah will be discussing the following:

Early detection and intervention in schizophrenia requires mechanism-based biomarkers that capture neural circuitry dysfunction, allowing better patient stratification, monitoring of disease progression and treatment.

In prefrontal cortex and blood of redox dysregulated mice, oxidative stress induces miR-137 upregulation, leading to decreased COX6A2 and mitophagy markers (NIX, Fundc1, and LC3B) and to accumulation of damaged mitochondria, further exacerbating oxidative stress and parvalbumin interneurons (PVI) impairment. MitoQ, a mitochondria-targeted antioxidant, rescued all these processes.

Translating to early psychosis patients (EPP), blood exosomal miR-137 increases and COX6A2 decreases, combined with mitophagy markers alterations, suggest that observations made centrally and peripherally in animal model were reflected in patients' blood extracellular vesicles. Higher exosomal miR-137 and lower COX6A2 levels were associated with a reduction of ASSR gamma oscillations in EEG.

As ASSR requires proper PVI-related networks, alterations in miR-137/COX6A2 plasma exosome levels may represent a proxy marker of PVI cortical microcircuit impairment. EPP can be stratified in two subgroups: (a) a patients' group with mitochondrial dysfunction "Psy-D", having high miR-137 and low COX6A2 levels in exosomes, and (b) a "Psy-ND" subgroup with no/low mitochondrial impairment, including patients having miR-137 and COX6A2 levels in the range of controls. Psy-D patients exhibited more impaired ASSR responses in association with worse psychopathological status, neurocognitive performance, and global and social functioning, suggesting that impairment of PVI mitochondria leads to more severe disease profiles.

This stratification would allow, with high selectivity and specificity, the selection of patients for treatments targeting brain mitochondria dysregulation and capture the clinical and functional efficacy of future clinical trials.

Targeting Mitochondria 2022 Congress
October 26-28, 2022 - Berlin, Germany 
wms-site.com